ライフサイエンスコーパス: organ graft

1 al immunity causes little or no damage to an organ graft.

2 ucial part of efforts to engineer vessel and organ grafts.

3 e difficult to manage in recipients of solid organ grafts.

4 resulted in tolerance to the bone marrow and organ grafts.

5 e method for inducing tolerance toward solid organ grafts.

6 ily promote inflammation and injury in solid organ grafts.

7 tion rates remain among the highest of solid organ grafts.

8 rodent models to induce immune tolerance to organ grafts.

9 logic reactions affecting transplanted solid organ grafts.

10 al strategy for prolonging survival of solid organ grafts.

11 mechanisms similar to those affecting solid organ grafts.

12 potential to prevent rejection of allogeneic organ grafts.

13 marrow chimerism induces tolerance to solid organ grafts.

14 nduce donor-specific tolerance to xenogeneic organ grafts.

15 ) are often tolerant of donor-specific solid organ grafts.

16 ng specific transplantation tolerance to pig organ grafts.

17 arterial tree of chronically rejecting solid organ grafts.

18 participate in the rejection of interspecies organ grafts.

19 as the highest rate of rejection among solid organ grafts.

20 or preservation and conditioning of marginal organ grafts.

21 that are indiscriminately used for all solid organ grafts.

22 (+) DCs or NKT cells abrogated chimerism and organ graft acceptance.

23 nority of cases, continued survival of solid organ grafts after transplantation depends on lifelong,

24 g at increasing the lifespan of vascularized organ grafts also have to take into consideration the re

25 ents who are less affected from an old-donor organ graft and conversely in whom a rather unfavorable

26 ents who are less affected from an old-donor organ graft and conversely in whom a rather unfavorable

27 processes, including the rejection of solid organ grafts and graft-versus-host disease (GVHD) follow

28 d donor-specific tolerance to MHC-mismatched organ grafts are important clinical goals.

29 Dynamic preservation of organ grafts by hypothermic machine perfusion (HMP) has

30 of life of patients with long-term surviving organ grafts by reducing the immunologic and nonimmunolo

31 to concurrently or subsequently placed solid organ grafts can be reliably achieved with limited numbe

32 The strategy, which is applicable for all organ grafts, constitutes a paradigm shift in transplant

33 was to determine whether tolerance to solid organ grafts could be induced in mice reconstituted with

34 allograft rejection, most cardiac and other organ grafts eventually succumb to chronic vasculopathy,

35 al equal to 1086 recipients of cadaver whole-organ grafts from donors ages 10-40 years who underwent

36 living donation or children receiving whole-organ grafts from pediatric donors.

37 liver transplants confer protection on other organ grafts from the same donor.

38 Tolerance to organ grafts has been achieved by establishing a state o

39 a to normothermia incurred on reperfusion of organ grafts has been delineated as a genuine factor con

40 Aberrant expression of HLA-G in human organ grafts has been proposed to contribute to graft ac

41 y factors contribute to the failure of a pig organ graft in a primate.

42 s variation between donors and recipients of organ grafts in tissue matching, innate immune reactivit

43 nfused donor marrow stem cells, syngeneic to organ grafts, in nonmyeloablated recipients.

44 s simultaneously infused donor (syngeneic to organ grafts) marrow stem cell engraftment, differentiat

45 consider that what we call accommodation of organ grafts may occur widely in the context of immune r

46 the potential influence of alloantibodies on organ graft outcome, this study investigated the inducti

47 Organ graft preservation injury is a major problem compl

48 ssive drug therapy-induced impairment of the organ graft recipient's immune surveillance is considere

49 rewarded with individualized therapy for the organ graft recipient.

50 ave reviewed the outcomes for cases of solid organ graft recipients from H1N1 influenza-positive dono

51 nd metastatic progression of malignancies in organ graft recipients.

52 ssociated with rejection of allogeneic solid organ grafts, regulatory T (T(reg)) cells appear to fost

53 MMF is being used for prevention of organ graft rejection and has also shown efficacy in rhe

54 s needed to overcome the problems of chronic organ graft rejection and immunosuppression-related toxi

55 phingosine 1-phosphate receptors to suppress organ graft rejection in humans and autoimmunity in anim

56 yeloblative total body irradiation prevented organ graft rejection, all hosts succumbed to lethal gra

57 unity, graft-versus-host disease (GVHD), and organ graft rejection.

58 s against both graft-versus-host disease and organ graft rejection.

59 ne disorders, T-cell malignancies, and solid organ graft rejection.

60 important mechanisms in atherosclerosis and organ graft rejection.

61 in the treatment of autoimmune disorders and organ graft rejection.

62 s the progression of autoimmune diseases and organ graft rejection.

63 has been associated with more risk for solid organ graft rejection.

64 can function as cellular effectors of solid organ graft rejection; however, the specific mechanisms

65 mesenchymal stromal cells can prolong solid organ graft survival and that they can induce immune tol

66 Posttransplantation organ graft survival at 1 and 12 months was compared.

67 ve association of PRA+ with allogeneic solid organ graft survival has been recognized, but scattered

68 s an effective approach to promote long-term organ graft survival.

69 ponses and markedly prolong heart and kidney organ graft survival.

70 n xenotransplantation that has permitted pig organ graft survivals of years in non-human primates has

71 tory events after transplant in solid tissue organ grafts that may direct T cell recruitment and prom

72 are critical for the rejection of some solid organ grafts, the role of CD4(+) T cells in the rejectio

73 c chimerism induces life-long donor-specific organ graft tolerance while obviating the need for chron

74 of early inflammatory events in vascularized organ grafts, we tested the intragraft expression of fou

75 Almost half of all transplanted vascularized organ grafts will be lost to transplant arteriosclerosis